Related Experiment Videos
Breast cancer: when tumor markers become targets for drugs
T Ojasoo1, M E Lippman, H Rochefort
1Pierre & Marie Curie University (VI), Paris, France.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
How to target estrogen receptor-negative breast cancer?
Endocrine-related cancer·2003
Mannose-6-phosphate/insulin-like growth factor-II receptor expression levels during the progression from normal human mammary tissue to invasive breast carcinomas.
European journal of cancer (Oxford, England : 1990)·2003
Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells.
The Journal of steroid biochemistry and molecular biology·2001
Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms.
Molecular endocrinology (Baltimore, Md.)·2000
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026